Phagos

PhagosPhagos
Phagos

Phagos

Phagos is developing bacteriophage therapies to combat antibiotic-resistant bacterial infections.

DR 312021Active74Boston, United States
Rate

About

Phagos is a biotechnology company focused on developing novel bacteriophage therapies to address the growing threat of antibiotic-resistant bacteria. Their approach leverages the natural predators of bacteria, phages, to create targeted and effective treatments for infections that are no longer responsive to conventional antibiotics.
Frequently asked

What does Phagos do?

Phagos is a biotechnology company focused on developing novel bacteriophage therapies to address the growing threat of antibiotic-resistant bacteria. Their approach leverages the natural predators of bacteria, phages, to create targeted and effective treatments for infections that are no longer responsive to conventional antibiotics.

What is Phagos's revenue?

StartupHub estimates Phagos's annual revenue at $10.9M (range $6.4M to $17.7M, 64% confidence), based on comparable companies in the sector.

What is Phagos's valuation?

StartupHub estimates Phagos's effective valuation at $111.2M (range $71.3M to $171.0M, 19% confidence), based on comparable companies in the sector.

How much funding has Phagos raised?

Phagos has raised a total of $29M in funding. The most recent round on record is Series A.

Where is Phagos headquartered?

Phagos is headquartered in Boston, United States.

When was Phagos founded?

Phagos was founded in 2021.

What industry does Phagos operate in?

Phagos operates in Biotech, MedTech, HealthTech, Drug Discovery, Phage Therapy, Antibiotic Resistance.

How many employees does Phagos have?

Phagos has approximately 74 people on record.

HEADCOUNT
74
DOMAIN RATING
31
Comments

No comments yet. Be the first to share your take.